{
    "organizations": [],
    "uuid": "019f3c12fbd6850a0c378e4846bee5a94b2a3487",
    "author": "",
    "url": "https://www.reuters.com/article/brief-celgene-to-acquire-remaining-share/brief-celgene-to-acquire-remaining-shares-of-juno-therapeutics-for-87-per-share-idUSASB0C1NE",
    "ord_in_thread": 0,
    "title": "BRIEF-Celgene To Acquire Remaining Shares Of Juno Therapeutics For $87 Per Share",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 36 AM / in 13 minutes BRIEF-Celgene To Acquire Remaining Shares Of Juno Therapeutics For $87 Per Share Reuters Staff \nJan 22  : \n* CELGENE CORPORATION TO ACQUIRE JUNO THERAPEUTICS, INC., ADVANCING GLOBAL LEADERSHIP IN CELLULAR IMMUNOTHERAPY \n* CELGENE CORPORATION TO ACQUIRE JUNO THERAPEUTICS, INC., ADVANCING GLOBAL LEADERSHIP IN CELLULAR IMMUNOTHERAPY * CELGENE CORP - DEAL FOR $87 PER SHARE \n* CELGENE CORP - REAFFIRMING 2020 FINANCIAL TARGETS OF $19B-$20B IN TOTAL NET PRODUCT SALES AND ADJUSTED EPS GREATER THAN $12.50 \n* CELGENE CORP - ‍TRANSACTION WAS APPROVED BY BOARDS OF DIRECTORS OF BOTH COMPANIES​ \n* CELGENE CORP - JCAR017 IS EXPECTED TO BE SIGNIFICANT GROWTH DRIVER BEYOND 2020 WITH POTENTIAL GLOBAL PEAK SALES OF APPROXIMATELY $3 BILLION \n* CELGENE CORP - CELGENE WILL PAY APPROXIMATELY $9 BILLION, NET OF CASH AND MARKETABLE SECURITIES ACQUIRED AND JUNO SHARES ALREADY OWNED BY CELGENE \n* CELGENE CORP - ‍ACQUISITION IS EXPECTED TO BE DILUTIVE TO ADJUSTED EPS IN 2018 BY APPROXIMATELY $0.50​ \n* CELGENE CORP - ‍REGULATORY APPROVAL FOR JCAR017 IN U.S. IS EXPECTED IN 2019 WITH POTENTIAL GLOBAL PEAK SALES OF APPROXIMATELY $3 BILLION​ \n* CELGENE CORP - DEAL ‍IS EXPECTED TO BE INCREMENTALLY ADDITIVE TO NET PRODUCT SALES IN 2020​ \n* CELGENE CORP - CELGENE EXPECTS TO FUND TRANSACTION THROUGH A COMBINATION OF EXISTING CASH AND NEW DEBT \n* CELGENE CORP - REGULATORY APPROVAL FOR JCAR017 IN U.S. IS EXPECTED IN 2019 Source text for Eikon: Further company coverage:",
    "published": "2018-01-22T13:36:00.000+02:00",
    "crawled": "2018-01-22T13:56:29.018+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "minute",
        "acquire",
        "remaining",
        "share",
        "juno",
        "therapeutic",
        "per",
        "share",
        "reuters",
        "staff",
        "jan",
        "celgene",
        "corporation",
        "acquire",
        "juno",
        "therapeutic",
        "advancing",
        "global",
        "leadership",
        "cellular",
        "immunotherapy",
        "celgene",
        "corporation",
        "acquire",
        "juno",
        "therapeutic",
        "advancing",
        "global",
        "leadership",
        "cellular",
        "immunotherapy",
        "celgene",
        "corp",
        "deal",
        "per",
        "share",
        "celgene",
        "corp",
        "reaffirming",
        "financial",
        "target",
        "20b",
        "total",
        "net",
        "product",
        "sale",
        "adjusted",
        "eps",
        "greater",
        "celgene",
        "corp",
        "approved",
        "board",
        "director",
        "celgene",
        "corp",
        "jcar017",
        "expected",
        "significant",
        "growth",
        "driver",
        "beyond",
        "potential",
        "global",
        "peak",
        "sale",
        "approximately",
        "billion",
        "celgene",
        "corp",
        "celgene",
        "pay",
        "approximately",
        "billion",
        "net",
        "cash",
        "marketable",
        "security",
        "acquired",
        "juno",
        "share",
        "already",
        "owned",
        "celgene",
        "celgene",
        "corp",
        "expected",
        "dilutive",
        "adjusted",
        "eps",
        "approximately",
        "celgene",
        "corp",
        "approval",
        "jcar017",
        "expected",
        "potential",
        "global",
        "peak",
        "sale",
        "approximately",
        "celgene",
        "corp",
        "deal",
        "expected",
        "incrementally",
        "additive",
        "net",
        "product",
        "sale",
        "celgene",
        "corp",
        "celgene",
        "expects",
        "fund",
        "transaction",
        "combination",
        "existing",
        "cash",
        "new",
        "debt",
        "celgene",
        "corp",
        "regulatory",
        "approval",
        "jcar017",
        "expected",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}